应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02181 迈博药业—B
休市中 07-19 16:08:12
0.360
+0.000
0.00%
最高
0.360
最低
0.360
成交量
6,000
今开
0.360
昨收
0.360
日振幅
0.00%
总市值
14.85亿
流通市值
14.85亿
总股本
41.24亿
成交额
2,160
换手率
0.00%
流通股本
41.24亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
迈博药业-B(02181)委任岑佳麟为非执行董事
智通财经 · 07-10
迈博药业-B(02181)委任岑佳麟为非执行董事
迈博药业-B盘中异动 早盘股价大跌24.24%报0.300港元
自选股智能写手 · 07-05
迈博药业-B盘中异动 早盘股价大跌24.24%报0.300港元
迈博药业(02181.HK)核心产品CMAB008获秘鲁上市注册申请
阿斯达克财经 · 07-03
迈博药业(02181.HK)核心产品CMAB008获秘鲁上市注册申请
迈博药业-B(02181):秘鲁卫生部批准核心产品CMAB008(注射用英夫利西单抗)的上市注册申请
智通财经 · 07-02
迈博药业-B(02181):秘鲁卫生部批准核心产品CMAB008(注射用英夫利西单抗)的上市注册申请
迈博药业-B盘中异动 临近收盘急速拉升8.49%
自选股智能写手 · 06-26
迈博药业-B盘中异动 临近收盘急速拉升8.49%
填补国产EGFR抗体新药空白!先声再明/迈博药业合作开发西妥昔单抗β获批上市
医药魔方 · 06-26
填补国产EGFR抗体新药空白!先声再明/迈博药业合作开发西妥昔单抗β获批上市
迈博药业-B(02181):国家药监局批准核心产品CMAB009恩立妥®(西妥昔单抗β注射液)的上市注册申请(NDA)
智通财经网 · 06-25
迈博药业-B(02181):国家药监局批准核心产品CMAB009恩立妥®(西妥昔单抗β注射液)的上市注册申请(NDA)
迈博药业(02181.HK):恩立妥获国家药监局批准上市
阿斯达克财经 · 06-25
迈博药业(02181.HK):恩立妥获国家药监局批准上市
迈博药业-B(02181)股价上升7.246%,现价港币$0.37
阿斯达克财经 · 06-06
迈博药业-B(02181)股价上升7.246%,现价港币$0.37
迈博药业-B盘中异动 早盘股价大涨7.25%
自选股智能写手 · 06-06
迈博药业-B盘中异动 早盘股价大涨7.25%
迈博药业-B盘中异动 临近收盘股价大涨8.86%
自选股智能写手 · 05-24
迈博药业-B盘中异动 临近收盘股价大涨8.86%
迈博药业-B盘中异动 股价大跌16.67%
自选股智能写手 · 05-23
迈博药业-B盘中异动 股价大跌16.67%
迈博药业-B盘中异动 下午盘股价大跌5.05%
自选股智能写手 · 05-07
迈博药业-B盘中异动 下午盘股价大跌5.05%
迈博药业-B(02181)股价下跌8.75%,现价港币$0.365
阿斯达克财经 · 05-02
迈博药业-B(02181)股价下跌8.75%,现价港币$0.365
迈博药业-B盘中异动 大幅下跌8.98%报0.365港元
自选股智能写手 · 05-02
迈博药业-B盘中异动 大幅下跌8.98%报0.365港元
迈博药业-B盘中异动 大幅下挫19.04%
自选股智能写手 · 04-30
迈博药业-B盘中异动 大幅下挫19.04%
迈博药业-B盘中异动 股价大跌7.98%
自选股智能写手 · 04-25
迈博药业-B盘中异动 股价大跌7.98%
迈博药业-B盘中异动 大幅下跌5.70%
自选股智能写手 · 04-16
迈博药业-B盘中异动 大幅下跌5.70%
迈博药业-B(02181)股价下跌5.319%,现价港币$0.445
阿斯达克财经 · 04-09
迈博药业-B(02181)股价下跌5.319%,现价港币$0.445
迈博药业-B盘中异动 早盘急速下挫5.11%报0.446港元
自选股智能写手 · 04-09
迈博药业-B盘中异动 早盘急速下挫5.11%报0.446港元
加载更多
公司概况
公司名称:
迈博药业—B
所属市场:
SEHK
上市日期:
--
主营业务:
迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要产品包括奥马珠单抗(CMAB007)、西妥昔单抗(CMAB009)和英夫利昔单抗(CMAB008)等。该公司主要在中国境内经营业务。
发行价格:
--
{"stockData":{"symbol":"02181","market":"HK","secType":"STK","nameCN":"迈博药业—B","latestPrice":0.36,"timestamp":1721376492014,"preClose":0.36,"halted":0,"volume":6000,"delay":0,"floatShares":4124080000,"shares":4124080000,"eps":-0.054416195,"marketStatus":"休市中","marketStatusCode":7,"change":0,"latestTime":"07-19 16:08:12","open":0.36,"high":0.36,"low":0.36,"amount":2160,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0.36,"bidSize":20000,"shortable":0,"etf":0,"ttmEps":-0.05441619471583765,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721611800000},"adr":0,"listingDate":1559232000000,"adjPreClose":0.36,"openAndCloseTimeList":[[1721352600000,1721361600000],[1721365200000,1721376000000]],"volumeRatio":2.5,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02181","defaultTab":"news","newsList":[{"id":"2450889997","title":"迈博药业-B(02181)委任岑佳麟为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2450889997","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450889997?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:10","pubTimestamp":1720613433,"startTime":"0","endTime":"0","summary":"智通财经APP讯,迈博药业-B(02181)公布,自2024年7月10日,岑佳麟先生将获委任为非执行董事;陶谦博士将获委任为独立非执行董事;公司现任非执行董事钱卫珠博士将获调任为执行董事,并将获委任为公司副总裁;及李云峰先生将获委任为公司副总裁,并将不再担任公司首席财务官。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02181","BK1574","BK1161"],"gpt_icon":0},{"id":"2449839283","title":"迈博药业-B盘中异动 早盘股价大跌24.24%报0.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449839283","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449839283?lang=zh_cn&edition=full","pubTime":"2024-07-05 10:10","pubTimestamp":1720145418,"startTime":"0","endTime":"0","summary":"2024年07月05日早盘10时10分,迈博药业-B股票出现波动,股价快速下挫24.24%。截至发稿,该股报0.300港元/股,成交量4000股,换手率0.00%,振幅0.00%。资金方面,该股资金流入0港元,流出1200港元。迈博药业-B股票所在的生物技术行业中,整体涨幅为0.54%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070510101896819c89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070510101896819c89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02181","BK1574"],"gpt_icon":0},{"id":"2448164192","title":"迈博药业(02181.HK)核心产品CMAB008获秘鲁上市注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2448164192","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448164192?lang=zh_cn&edition=full","pubTime":"2024-07-03 00:50","pubTimestamp":1719939000,"startTime":"0","endTime":"0","summary":"迈博药业-B(02181.HK) 公布,近 日,公司核心产品之一CMAB008类停(注射用英夫利西单抗)的上市注册申请获秘鲁卫生部批准,用于治疗:成人溃疡性结肠炎;强直性脊柱炎;类风湿关节炎;及银屑病等。CMAB008类停为首个获准上市的内地生产之英夫利西单抗,是公司自主研发的单克隆抗体生物类似药,已列入中国基本医疗保险药品目录。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201022164819888_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201022164819888_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1360894/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02181","BK1574"],"gpt_icon":0},{"id":"2448273136","title":"迈博药业-B(02181):秘鲁卫生部批准核心产品CMAB008(注射用英夫利西单抗)的上市注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2448273136","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448273136?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:11","pubTimestamp":1719915110,"startTime":"0","endTime":"0","summary":"智通财经APP讯,迈博药业-B(02181)发布公告,近日,公司核心产品之一,自主开发的重组抗肿瘤坏死因子α人鼠嵌合单克隆抗体CMAB008类停®(注射用英夫利西单抗)的上市注册申请获秘鲁卫生部批准,用于治疗:(i)成人溃疡性结肠炎;(ii)强直性嵴柱炎;(iii)类风湿关节炎;(iv)成人及6岁以上儿童克罗恩病;(v)瘘管性克罗恩病;及(vi)银屑病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02181"],"gpt_icon":0},{"id":"2446589113","title":"迈博药业-B盘中异动 临近收盘急速拉升8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446589113","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446589113?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:42","pubTimestamp":1719387730,"startTime":"0","endTime":"0","summary":"2024年06月26日临近收盘15时42分,迈博药业-B股票出现异动,股价快速上涨8.49%。截至发稿,该股报0.396港元/股,成交量2000股,换手率0.00%,振幅0.00%。迈博药业-B股票所在的生物技术行业中,整体跌幅为0.22%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062615421096817098&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062615421096817098&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02257","BK1161","02181"],"gpt_icon":0},{"id":"2446067738","title":"填补国产EGFR抗体新药空白!先声再明/迈博药业合作开发西妥昔单抗β获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446067738","media":"医药魔方","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446067738?lang=zh_cn&edition=full","pubTime":"2024-06-26 07:47","pubTimestamp":1719359239,"startTime":"0","endTime":"0","summary":"6月25日,先声药业集团旗下抗肿瘤创新药公司先声再明宣布,与迈博药业合作开发的新一代EGFR抗体药物恩立妥已于近日获国家药品监督管理局批准上市,适应症为与FOLFIRI方案联合用于一线治疗RAS/BRAF基因野生型的转移性结直肠癌。全球已上市的另一款结直肠癌EGFR抗体药物为帕尼单抗。作为一款全人源EFGR抗体,该药物上市后大规模临床研究并未支持其在疗效或安全性上优于西妥昔单抗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260754219f65878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260754219f65878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02181"],"gpt_icon":0},{"id":"2446894506","title":"迈博药业-B(02181):国家药监局批准核心产品CMAB009恩立妥®(西妥昔单抗β注射液)的上市注册申请(NDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2446894506","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446894506?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:00","pubTimestamp":1719306016,"startTime":"0","endTime":"0","summary":"迈博药业-B(02181)发布公告,近日,公司核心产品之一,CMAB009恩立妥®...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2446189441","title":"迈博药业(02181.HK):恩立妥获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446189441","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446189441?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:00","pubTimestamp":1719306000,"startTime":"0","endTime":"0","summary":"迈博药业(02181.HK) 公布,近日公司核心产品之一,CMAB009恩立妥的上市注册申请(NDA)获中国国家药品监督管理局批准,其与FOLFIRI方案联合用于RAS/BRAF基因野生型的转移性结直肠癌(mCRC)的一线治疗。(sl/k)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201022164820841_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201022164820841_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359017/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2441315753","title":"迈博药业-B(02181)股价上升7.246%,现价港币$0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2441315753","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441315753?lang=zh_cn&edition=full","pubTime":"2024-06-06 10:50","pubTimestamp":1717642200,"startTime":"0","endTime":"0","summary":"[上升股]迈博药业-B(02181) 股价在上午10:50比前收市价上升7.246%,现股价为港币$0.37。至目前为止,今日最高价为$0.37,而最低价为$0.355。总成交量为5万股,总成交金额为港币$1.793万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406061821/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02181","BK1574","BK1161"],"gpt_icon":0},{"id":"2441758658","title":"迈博药业-B盘中异动 早盘股价大涨7.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441758658","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441758658?lang=zh_cn&edition=full","pubTime":"2024-06-06 10:45","pubTimestamp":1717641947,"startTime":"0","endTime":"0","summary":"2024年06月06日早盘10时45分,迈博药业-B股票出现波动,股价大幅上涨7.25%。迈博药业-B股票所在的生物技术行业中,整体跌幅为0.04%。其相关个股中,迈博药业-B、北海康成-B、泰格医药涨幅较大,振幅较大的相关个股有康宁杰瑞制药-B、云顶新耀-B、科济药业-B,振幅分别为10.93%、7.88%、7.63%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240606104547af8c4b93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240606104547af8c4b93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2437478704","title":"迈博药业-B盘中异动 临近收盘股价大涨8.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437478704","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437478704?lang=zh_cn&edition=full","pubTime":"2024-05-24 15:59","pubTimestamp":1716537576,"startTime":"0","endTime":"0","summary":"2024年05月24日临近收盘15时59分,迈博药业-B股票出现异动,股价大幅拉升8.86%。截至发稿,该股报0.381港元/股,成交量1.4万股,换手率0.00%,振幅0.00%。迈博药业-B股票所在的生物技术行业中,整体跌幅为2.18%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524155936941e9fb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524155936941e9fb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02181","02487","BK1574","02898","01244"],"gpt_icon":0},{"id":"2437162273","title":"迈博药业-B盘中异动 股价大跌16.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437162273","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437162273?lang=zh_cn&edition=full","pubTime":"2024-05-23 09:54","pubTimestamp":1716429269,"startTime":"0","endTime":"0","summary":"2024年05月23日早盘09时54分,迈博药业-B股票出现异动,股价急速下跌16.67%。迈博药业-B股票所在的生物技术行业中,整体跌幅为1.09%。其相关个股中,北海康成-B、来凯医药-B、康希诺生物涨幅较大,振幅较大的相关个股有和铂医药-B、康希诺生物、来凯医药-B,振幅分别为13.57%、9.13%、6.60%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240523095429aef134e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240523095429aef134e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02181","BK1161","BK1574","02105"],"gpt_icon":0},{"id":"2433463132","title":"迈博药业-B盘中异动 下午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433463132","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433463132?lang=zh_cn&edition=full","pubTime":"2024-05-07 15:04","pubTimestamp":1715065490,"startTime":"0","endTime":"0","summary":"2024年05月07日下午盘15时04分,迈博药业-B股票出现波动,股价快速下挫5.05%。截至发稿,该股报0.376港元/股,成交量0股,换手率0.00%,振幅0.00%。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。迈博药业-B股票所在的生物技术行业中,整体跌幅为1.16%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050715045187e860fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050715045187e860fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02181","BK1161","01167"],"gpt_icon":0},{"id":"2432203618","title":"迈博药业-B(02181)股价下跌8.75%,现价港币$0.365","url":"https://stock-news.laohu8.com/highlight/detail?id=2432203618","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432203618?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:29","pubTimestamp":1714620540,"startTime":"0","endTime":"0","summary":"[下跌股]迈博药业-B(02181) 股价在上午11:29比前收市价下跌8.75%,现股价为港币$0.365。至目前为止,今日最高价为$0.365,而最低价为$0.365。总成交量为2000股,总成交金额为港币$730。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2405022871/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","02181"],"gpt_icon":0},{"id":"2432869792","title":"迈博药业-B盘中异动 大幅下跌8.98%报0.365港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432869792","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432869792?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:04","pubTimestamp":1714619055,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘11时04分,迈博药业-B股票出现异动,股价大幅跳水8.98%。截至发稿,该股报0.365港元/股,成交量0股,换手率0.00%,振幅0.00%。迈博药业-B股票所在的生物技术行业中,整体涨幅为0.85%。其相关个股中,加科思-B、康希诺生物、基石药业-B涨幅较大,振幅较大的相关个股有加科思-B、基石药业-B、科笛-B,振幅分别为14.20%、11.36%、11.34%。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021104157a57e5b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021104157a57e5b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","BK1574","BK1161","02181"],"gpt_icon":0},{"id":"2431330288","title":"迈博药业-B盘中异动 大幅下挫19.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431330288","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431330288?lang=zh_cn&edition=full","pubTime":"2024-04-30 13:12","pubTimestamp":1714453965,"startTime":"0","endTime":"0","summary":"2024年04月30日下午盘13时12分,迈博药业-B股票出现波动,股价快速下跌19.04%。迈博药业-B股票所在的生物技术行业中,整体跌幅为0.43%。其相关个股中,北海康成-B、博安生物、科济药业-B涨幅较大,振幅较大的相关个股有科笛-B、乐普生物-B、科伦博泰生物-B,振幅分别为27.56%、15.86%、13.64%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430131245861ea52d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430131245861ea52d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02181","BK1574"],"gpt_icon":0},{"id":"2430450124","title":"迈博药业-B盘中异动 股价大跌7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430450124","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430450124?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:36","pubTimestamp":1714016200,"startTime":"0","endTime":"0","summary":"2024年04月25日临近午盘11时36分,迈博药业-B股票出现异动,股价急速下跌7.98%。迈博药业-B股票所在的生物技术行业中,整体涨幅为1.41%。其相关个股中,维亚生物、3D MEDICINES、科济药业-B涨幅较大,振幅较大的相关个股有科济药业-B、北海康成-B、来凯医药-B,振幅分别为16.04%、14.89%、14.07%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511364087e83693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511364087e83693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1161","02181","BK1574","02171","BK1587","01244"],"gpt_icon":0},{"id":"2427868495","title":"迈博药业-B盘中异动 大幅下跌5.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427868495","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427868495?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:53","pubTimestamp":1713232417,"startTime":"0","endTime":"0","summary":"2024年04月16日早盘09时53分,迈博药业-B股票出现波动,股价大幅跳水5.70%。截至发稿,该股报0.430港元/股,成交量2000股,换手率0.00%,振幅0.00%。迈博药业-B股票所在的生物技术行业中,整体跌幅为0.28%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160953377920c034&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160953377920c034&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02181","BK1574","02257"],"gpt_icon":0},{"id":"2426183301","title":"迈博药业-B(02181)股价下跌5.319%,现价港币$0.445","url":"https://stock-news.laohu8.com/highlight/detail?id=2426183301","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426183301?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:50","pubTimestamp":1712631000,"startTime":"0","endTime":"0","summary":"[下跌股]迈博药业-B(02181) 股价在上午10:50比前收市价下跌5.319%,现股价为港币$0.445。至目前为止,今日最高价为$0.45,而最低价为$0.445。总成交量为5.6万股,总成交金额为港币$2.517万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404091042/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2426188161","title":"迈博药业-B盘中异动 早盘急速下挫5.11%报0.446港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426188161","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426188161?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:43","pubTimestamp":1712630604,"startTime":"0","endTime":"0","summary":"2024年04月09日早盘10时43分,迈博药业-B股票出现波动,股价快速下跌5.11%。截至发稿,该股报0.446港元/股,成交量5万股,换手率0.00%,振幅0.00%。资金方面,该股资金流入2.25万港元,流出0港元。迈博药业-B股票所在的生物技术行业中,整体涨幅为0.11%。迈博药业-B公司简介:迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409104326791f4a0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409104326791f4a0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02181","BK1161","BK1574","01541"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabpharm.cn","stockEarnings":[{"period":"1week","weight":0.0286},{"period":"1month","weight":-0.0137},{"period":"3month","weight":-0.1529},{"period":"6month","weight":0.2414},{"period":"1year","weight":-0.52},{"period":"ytd","weight":-0.2174}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要产品包括奥马珠单抗(CMAB007)、西妥昔单抗(CMAB009)和英夫利昔单抗(CMAB008)等。该公司主要在中国境内经营业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.068013},{"month":2,"riseRate":0.8,"avgChangeRate":0.047861},{"month":3,"riseRate":0.8,"avgChangeRate":0.127909},{"month":4,"riseRate":0.4,"avgChangeRate":-0.050112},{"month":5,"riseRate":0.4,"avgChangeRate":-0.099942},{"month":6,"riseRate":0.666667,"avgChangeRate":0.103152},{"month":7,"riseRate":0.333333,"avgChangeRate":0.021962},{"month":8,"riseRate":0.2,"avgChangeRate":-0.169124},{"month":9,"riseRate":0,"avgChangeRate":-0.097886},{"month":10,"riseRate":0.6,"avgChangeRate":0.057868},{"month":11,"riseRate":0.6,"avgChangeRate":0.003886},{"month":12,"riseRate":0.6,"avgChangeRate":0.010639}],"exchange":"SEHK","name":"迈博药业—B","nameEN":"MABPHARM-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈博药业—B(02181)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈博药业—B(02181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈博药业—B,02181,迈博药业—B股票,迈博药业—B股票老虎,迈博药业—B股票老虎国际,迈博药业—B行情,迈博药业—B股票行情,迈博药业—B股价,迈博药业—B股市,迈博药业—B股票价格,迈博药业—B股票交易,迈博药业—B股票购买,迈博药业—B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈博药业—B(02181)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈博药业—B(02181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}